Trevi Therapeutics Inc [TRVI] stock prices are down -0.75% to $13.19 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TRVI shares have gain 23.85% over the last week, with a monthly amount glided 24.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Trevi Therapeutics Inc [NASDAQ: TRVI] stock has seen the most recent analyst activity on November 13, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $13. Previously, Morgan Stanley started tracking the stock with Overweight rating on August 21, 2025, and set its price target to $18. On July 01, 2025, Cantor Fitzgerald initiated with an Overweight rating and assigned a price target of $25 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $21 on May 28, 2025. Raymond James upgraded its rating to a Strong Buy and raised its price target to $29 on March 10, 2025. Needham reiterated a Buy rating for this stock on March 10, 2025, and upped its price target to $25. In a note dated December 12, 2024, H.C. Wainwright reiterated a Buy rating on this stock and boosted its target price from $6 to $7.50.
The stock price of Trevi Therapeutics Inc [TRVI] has been fluctuating between $2.36 and $13.73 over the past year. Currently, Wall Street analysts expect the stock to reach $19.67 within the next 12 months. Trevi Therapeutics Inc [NASDAQ: TRVI] shares were valued at $13.19 at the most recent close of the market. An investor can expect a potential return of 49.13% based on the average TRVI price forecast.
Analyzing the TRVI fundamentals
Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at -351.72%, Pretax Profit Margin comes in at -314.31%, and Net Profit Margin reading is -314.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.31 and Total Capital is -0.27. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.92 points at the first support level, and at 12.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.62, and for the 2nd resistance point, it is at 14.05.
Ratios To Look Out For
It’s worth pointing out that Trevi Therapeutics Inc [NASDAQ:TRVI]’s Current Ratio is 21.93. As well, the Quick Ratio is 21.93, while the Cash Ratio is 6.29.
Transactions by insiders
Recent insider trading involved Delfini Lisa, Officer, that happened on Oct 07 ’25 when 0.11 million shares were purchased. Officer, Delfini Lisa completed a deal on Oct 03 ’25 to buy 40000.0 shares. Meanwhile, Officer Delfini Lisa bought 0.31 million shares on Aug 27 ’25.
